PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study...
Year: 2022
Burning Rock Announces Publication of Prospectus in connection with Direct Listing on the London Stock Exchange
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA,...
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused...
Syneos Health Adds HUB Patient Suite to Deployment Solutions Business
Brings Together the Industry’s Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to AdherenceMORRISVILLE, N.C., Oct....
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...
OpGen to Provide Business Update and Financial Results for the Third Quarter 2022 on November 10th at 4:30 p.m. Eastern Standard Time
ROCKVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the...
OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update
Preliminary Total Revenue for Q3 2022 was approximately $0.4 millionCash as of September 30, 2022 was approximately $10.3 million and...
LEXEO Therapeutics to Present Clinical and Preclinical Data at Upcoming Scientific Conferences
- Presentations at the International Congress for Ataxia Research (ICAR) will feature LEXEO’s LX2006 gene therapy program for Friedreich’s ataxia...
Jushi Holdings Inc. Launches Newly Formulated Cannabis Infused Fruit Chews by Tasteology
Made with the Finest Real Fruit Purées by Ponthier and Crafted by Five-Star Chef — Innovative Vegan, Gluten-Free Chews Available in...
iSpecimen Launches New Open Feasibilities Dashboard on the iSpecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner Network
New Feature Provides Suppliers with Research Transparency to Optimize Fulfillment ProcessLEXINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc....
Kura Oncology to Report Third Quarter 2022 Financial Results
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2022
BANNOCKBURN, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH),...
Aurora Spine Corporation Announces Positive Interim Results from Clinical Study using ZIP™ MIS Interspinous Fusion System
Initial results show ZIP device to be effective and safeCARLSBAD, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation...
Indigo Diabetes Incorporates Fully Owned Subsidiary in the US and Appoints Peter J. Devlin as President, Indigo Medical US Inc.
PRESS RELEASE Indigo Diabetes Incorporates Fully Owned Subsidiary in the US and Appoints Peter J. Devlin as President, Indigo Medical...
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of...
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022
NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
TELA Bio to Announce Third Quarter 2022 Financial Results
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing...
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute has been awarded a $25,000 monetary prize recognizing her innovation in the field...